Patents by Inventor Jessica R. Kirshner
Jessica R. Kirshner has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20230272111Abstract: Mucin 16 (MUC16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human IgG antibodies that bind to human and MUC16 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both MUC16 and CD3 and activate T cells via the CD3 complex in the presence of MUC16-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds human and monkey MUC16. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing MUC16.Type: ApplicationFiled: September 26, 2022Publication date: August 31, 2023Inventors: Lauric Haber, Eric Smith, Marcus Kelly, Jessica R. Kirshner, Sandra Coetzee, Alison Crawford, Thomas Nittoli, Yashu Liu
-
Publication number: 20230220101Abstract: The present invention provides bispecific antibodies that bind to CD3 and tumor antigens and methods of using the same. According to certain embodiments, the bispecific antibodies of the invention exhibit reduced effector functions and have a unique binding profile with regard to Fc? receptors. The bispecific antibodies are engineered to efficiently induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, a second antigen-binding molecule that specifically binds human CD20, and an Fc domain that binds Fc? receptors with a specific binding pattern. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell or melanoma tumors expressing CD20.Type: ApplicationFiled: July 27, 2022Publication date: July 13, 2023Inventors: Eric Smith, Samuel Davis, Bindu Varghese, Jessica R. Kirshner, Gavin Thurston
-
Patent number: 11633501Abstract: The protein known as six-transmembrane epithelial antigen of prostate 2 (STEAP2) is highly expressed in prostate cancer and is associated with the expression of other prostate cancer-associated genes. The present invention provides novel full-length human IgG antibodies that bind to human STEAP2 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both STEAP2 and CD3 and activate T cells via the CD3 complex in the presence of STEAP2-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds humanSTEAP2. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing STEAP2.Type: GrantFiled: August 13, 2020Date of Patent: April 25, 2023Assignee: Regeneron Pharmaceuticals, Inc.Inventors: John Rudge, Frank Delfino, Lauric Haber, Eric Smith, Jessica R. Kirshner, Alison Crawford, Thomas Nittoli
-
Patent number: 11608380Abstract: The present invention provides antibodies that bind to the class Ill variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.Type: GrantFiled: July 1, 2020Date of Patent: March 21, 2023Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Jessica R. Kirshner, Douglas MacDonald, Gavin Thurston, Joel H. Martin, Frank Delfino, Thomas Nittoli, Marcus Kelly
-
Patent number: 11485793Abstract: Mucin 16 (MUC16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human IgG antibodies that bind to human and MUC16 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both MUC16 and CD3 and activate T cells via the CD3 complex in the presence of MUC16-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds human and monkey MUC16. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing MUC16.Type: GrantFiled: June 26, 2020Date of Patent: November 1, 2022Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lauric Haber, Eric Smith, Marcus Kelly, Jessica R. Kirshner, Sandra Coetzee, Alison Crawford, Thomas Nittoli, Yashu Liu
-
Patent number: 11434300Abstract: The present invention provides bispecific antibodies that bind to CD3 and tumor antigens and methods of using the same. According to certain embodiments, the bispecific antibodies of the invention exhibit reduced effector functions and have a unique binding profile with regard to Fc? receptors. The bispecific antibodies are engineered to efficiently induce T cell-mediated killing of tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, a second antigen-binding molecule that specifically binds human CD20, and an Fc domain that binds Fc? receptors with a specific binding pattern. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of B-cell or melanoma tumors expressing CD20.Type: GrantFiled: December 17, 2019Date of Patent: September 6, 2022Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Eric Smith, Samuel Davis, Bindu Varghese, Jessica R. Kirshner, Gavin Thurston
-
Publication number: 20210403595Abstract: The present invention provides antibodies that bind to prostate-specific membrane antigen (PSMA), bispecific antibodies that bind to PSMA and CD3, and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PSMA with high affinity and bind CD3 to induce human T cell proliferation. The invention includes antibodies that bind PSMA and CD3 and induce T cell-mediated killing of PSMA-expressing tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of prostate tumors expressing PSMA.Type: ApplicationFiled: September 16, 2021Publication date: December 30, 2021Inventors: Jessica R. Kirshner, Alison Crawford, Gavin Thurston, Eric Smith, Lauric Haber, Drew Dudgeon, Ashique Rafique
-
Patent number: 11155633Abstract: The present invention provides antibodies that bind to prostate-specific membrane antigen (PSMA), bispecific antibodies that bind to PSMA and CD3, and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PSMA with high affinity and bind CD3 to induce human T cell proliferation. The invention includes antibodies that bind PSMA and CD3 and induce T cell-mediated killing of PSMA-expressing tumor cells. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human PSMA. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of prostate tumors expressing PSMA.Type: GrantFiled: November 30, 2018Date of Patent: October 26, 2021Assignee: Regeneran Pharmaceuticals, Inc.Inventors: Jessica R. Kirshner, Alison Crawford, Gavin Thurston, Eric Smith, Lauric Haber, Drew Dudgeon, Ashique Rafique
-
Publication number: 20210147557Abstract: The present invention provides antibodies that bind to the class Ill variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.Type: ApplicationFiled: July 1, 2020Publication date: May 20, 2021Inventors: Jessica R. KIRSHNER, Douglas MACDONALD, Gavin THURSTON, Joel H. MARTIN, Frank DELFINO, Thomas NITTOLI, Marcus KELLY
-
Patent number: 10941208Abstract: Mucin 16 (MUC16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human IgG antibodies that bind to human MUC16 (monospecific antibodies) and antigen-binding fragments thereof. In some embodiments, the anti-MUC16 antibodies and the antigen-binding fragments thereof are useful in diagnostic methods for identifying the presence of MUC16 in tissue and/or plasma samples.Type: GrantFiled: September 22, 2017Date of Patent: March 9, 2021Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lauric Haber, Eric Smith, Marcus Kelly, Jessica R. Kirshner, Sandra Coetzee, Alison Crawford, Thomas Nittoli, Yashu Liu
-
Publication number: 20200399372Abstract: Provided herein are methods of treating cancer using bispecific antigen-binding molecules that bind to prostate-specific membrane antigen (PSMA) and CD3. According to certain embodiments, the antibodies useful herein bind human PSMA with high affinity and bind CD3 to induce human T cell proliferation. According to certain embodiments, bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human PSMA are particularly useful herein. In certain embodiments, the bispecific antigen-binding molecules in combination with an anti-4-1BB agonist are capable of inhibiting the growth of prostate tumors expressing PSMA.Type: ApplicationFiled: June 19, 2020Publication date: December 24, 2020Inventors: Jessica R. Kirshner, Alison Crawford, Danica Chiu
-
Publication number: 20200399371Abstract: Provided herein are method of treating cancer using bispecific antigen-binding molecules that bind to Mucin 16 (MUC16) and CD3. According to certain embodiments, the antibodies useful herein bind human MUC16 with high affinity and bind CD3 to induce human T cell proliferation. According to certain embodiments, bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human CD3, and a second antigen-binding molecule that specifically binds human MUC16 are particularly useful herein. In certain embodiments, the bispecific antigen-binding molecules in combination with an anti-4-1BB agonist are capable of inhibiting the growth of tumors expressing MUC16, for example, ovarian tumors.Type: ApplicationFiled: June 19, 2020Publication date: December 24, 2020Inventors: Jessica R. Kirshner, Alison Crawford, Danica Chiu
-
Publication number: 20200376136Abstract: The protein known as six-transmembrane epithelial antigen of prostate 2 (STEAP2) is highly expressed in prostate cancer and is associated with the expression of other prostate cancer-associated genes. The present invention provides novel full-length human IgG antibodies that bind to human STEAP2 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both STEAP2 and CD3 and activate T cells via the CD3 complex in the presence of STEAP2-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds humanSTEAP2. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing STEAP2.Type: ApplicationFiled: August 13, 2020Publication date: December 3, 2020Inventors: John Rudge, Frank Delfino, Lauric Haber, Eric Smith, Jessica R. Kirshner, Alison Crawford, Thomas Nittoli
-
Patent number: 10806780Abstract: The present invention provides antigen-binding proteins that specifically bind to an HLA-displayed human papillomavirus (HPV) peptide, and therapeutic and diagnostic methods of using those binding proteins.Type: GrantFiled: June 27, 2018Date of Patent: October 20, 2020Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Kevin A. Bray, Frank Delfino, Matthew C. Franklin, Elena S. Garnova, Jessica R. Kirshner, Douglas MacDonald, William Olson, Gavin Thurston
-
Publication number: 20200317810Abstract: Mucin 16 (MUC16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human IgG antibodies that bind to human andMUC16 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both MUC16 and CD3 and activate T cells via the CD3 complex in the presence of MUC16-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds human and monkey MUC16. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing MUC16.Type: ApplicationFiled: June 26, 2020Publication date: October 8, 2020Inventors: Lauric Haber, Eric Smith, Marcus Kelly, Jessica R. Kirshner, Sandra Coetzee, Alison Crawford, Thomas Nittoli, Yashu Liu
-
Patent number: 10772972Abstract: The protein known as six-transmembrane epithelial antigen of prostate 2 (STEAP2) is highly expressed in prostate cancer and is associated with the expression of other prostate cancer-associated genes. The present invention provides novel full-length human IgG antibodies that bind to human STEAP2 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both STEAP2 and CD3 and activate T cells via the CD3 complex in the presence of STEAP2-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds human STEAP2. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing STEAP2.Type: GrantFiled: September 22, 2017Date of Patent: September 15, 2020Assignee: Regeneron Pharmaceuticals, Inc.Inventors: John Rudge, Frank Delfino, Lauric Haber, Eric Smith, Jessica R. Kirshner, Alison Crawford, Thomas Nittoli
-
Patent number: 10738124Abstract: The present invention provides antibodies that bind to the class III variant of EGFR (EGFRvIII) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human EGFRvIII with high affinity. The antibodies of the invention may be fully human antibodies. The invention includes anti-EGFRvIII antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers.Type: GrantFiled: July 12, 2018Date of Patent: August 11, 2020Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Jessica R. Kirshner, Douglas MacDonald, Gavin Thurston, Joel H. Martin, Frank Delfino, Thomas Nittoli, Marcus Kelly
-
Patent number: 10738130Abstract: Mucin 16 (MUC16) is highly expressed in ovarian cancer and expression on cancer cells is shown to protect tumor cells from the immune system. The present invention provides novel full-length human IgG antibodies that bind to human and MUC16 (monospecific antibodies). The present invention also provides novel bispecific antibodies (bsAbs) that bind to both MUC16 and CD3 and activate T cells via the CD3 complex in the presence of MUC16-expressing tumors. According to certain embodiments, the present invention provides bispecific antigen-binding molecules comprising a first antigen-binding domain that specifically binds human and monkey CD3, and a second antigen-binding molecule that specifically binds human and monkey MUC16. In certain embodiments, the bispecific antigen-binding molecules of the present invention are capable of inhibiting the growth of tumors expressing MUC16.Type: GrantFiled: September 22, 2017Date of Patent: August 11, 2020Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Lauric Haber, Eric Smith, Marcus Kelly, Jessica R. Kirshner, Sandra Coetzee, Alison Crawford, Thomas Nittoli, Yashu Liu
-
Patent number: 10683354Abstract: The present invention provides antibodies that bind to prolactin receptor (PRLR) and methods of using the same. According to certain embodiments, the antibodies of the invention bind human PRLR with high affinity. In certain embodiments, the invention includes antibodies that bind PRLR and block prolactin-mediated cell signaling. In other embodiments, the invention includes antibodies that bind PRLR but do not block prolactin-mediated cell signaling. The antibodies of the invention may be fully human antibodies. The invention includes anti-PRLR antibodies conjugated to a cytotoxic agent, radionuclide, or other moiety detrimental to cell growth or proliferation. The antibodies of the invention are useful for the treatment of various cancers as well as other PRLR-related disorders.Type: GrantFiled: September 18, 2018Date of Patent: June 16, 2020Assignee: REGENERON PHARMACEUTICALS, INC.Inventors: Nicholas J. Papadopoulos, Gavin Thurston, Jessica R. Kirshner, Marcus P. Kelly, Thomas Nittoli, Frank J. Delfino
-
Patent number: 10662244Abstract: The present invention relates to a method (dosage regimen) for administering a CD3×CD20 bispecific antibody to a human patient, comprising (a) administering a first dose of said antibody in a specific dosage; and consecutively (b) administering a second dose of said antibody after a period of time, wherein said second dose exceeds said first dose. The methods of the invention (and likewise the dosage regimen of the invention) are also suitable for treating B cell (CD20-positive) cancer in a human patient, or for ameliorating and/or preventing a medical condition mediated by the periodic or continued administration of a CD3×CD20 bispecific antibody to a human patient. The present invention also relates to the use of a CD3×CD20 bispecific antibody for the preparation of a pharmaceutical composition to be used in a method or treatment regime as defined in any one of the preceding claims.Type: GrantFiled: November 17, 2015Date of Patent: May 26, 2020Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Eric Smith, Samuel Davis, Bindu Varghese, Jessica R. Kirshner, Gavin Thurston, Israel Lowy, Carrie Brownstein